UBS Maintains a 'Neutral' on Cephalon (CEPH); Distracted 1Q11
Tweet
Share
E-mailGet Alerts CEPH Hot Sheet
Price: $81.49 --0%
Rating Summary:
1 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
1 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
UBS maintains a 'Neutral' on Cephalon (NASDAQ: CEPH), PT increased from $78 to $81.50.
UBS analyst says, "Thoughts on the stock: We expect the Teva (Nasdaq: TEVA) deal to close With Valeant (NYSE: VRX) stepping down and Teva’s bid at a level we believe shareholders will be happy with and a level supported by Cephalon, we expect Teva to close its acquisition of Cephalon and no other bidders to emerge."
For more ratings news on Cephalon click here and for the rating history of Cephalon click here.
Shares of Cephalon closed at $79.99 yesterday.
UBS analyst says, "Thoughts on the stock: We expect the Teva (Nasdaq: TEVA) deal to close With Valeant (NYSE: VRX) stepping down and Teva’s bid at a level we believe shareholders will be happy with and a level supported by Cephalon, we expect Teva to close its acquisition of Cephalon and no other bidders to emerge."
For more ratings news on Cephalon click here and for the rating history of Cephalon click here.
Shares of Cephalon closed at $79.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- NetEase.com (NTES) PT Raised to $168 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
